Abstract
Two paenipeptin analogues at 4 μg/ml potentiated clarithromycin and rifampin against carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae strains. The combined treatment significantly increased their antibacterial efficacy in a microbiological medium and in human serum in vitro at therapeutically relevant concentrations. Moreover, these two paenipeptin analogues showed low cytotoxicity against a human kidney cell line. Therefore, combination therapy with paenipeptins may be an option for the treatment of antibiotic-resistant bacterial infections.
Keywords:
clarithromycin; combination therapy; lipopeptide; paenipeptin; rifampin.
Copyright © 2018 American Society for Microbiology.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acinetobacter baumannii / drug effects*
-
Acinetobacter baumannii / growth & development
-
Acinetobacter baumannii / pathogenicity
-
Anti-Bacterial Agents / pharmacology*
-
Carbapenems / pharmacology
-
Cell Survival / drug effects
-
Clarithromycin / pharmacology*
-
Drug Combinations
-
Drug Synergism
-
HEK293 Cells
-
Humans
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / growth & development
-
Klebsiella pneumoniae / pathogenicity
-
Lipopeptides / chemical synthesis
-
Lipopeptides / pharmacology*
-
Microbial Sensitivity Tests
-
Rifampin / pharmacology*
-
beta-Lactam Resistance / drug effects
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Drug Combinations
-
Lipopeptides
-
Clarithromycin
-
Rifampin